FDA: Hospira recalls three lots of hydromorphone HCL injection
Editor's Note
The Food & Drug Administration (FDA) on March 5 announced the recall by Hospira (Lake Forest, Illinois) of three lots of hydromorphone HCL injection, USP Cll 10 mg/mL, 1 mL in 2 mL single dose vials.
The recall was initiated because units from these lots may be empty or cracked at the bottom of the glass vial. Cracked vials my compromise sterility of the product, and exposure to cracked vials may be associated with sharps injuries.
Lot numbers are 71330DD (NDC 0409-2634-01) as well as 691853F and 700753F (NDC 0703-0110-01-Teva lots).
Posted 03/05/2018] AUDIENCE: Pharmacy, Risk Manager ISSUE: Hospira is voluntarily recalling three lots of Hydromorphone HCl Injection, USP CII 10 mg/mL, 1 mL in 2 mL Single Dose Vials lot numbers 71330DD (NDC 0409-2634-01), and 691853F and 700753F (NDC 0703-0110-01 - Teva lots) to the hospital/institution level.
Free Daily News
- Study: COVID-19's impact on oncological surgery offers lessons for future crises
- Study links pandemic stress to persistent increases in nursing-sensitive quality indicators
- Save the date for the 2025 OR Business Management Conference
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO